Cincinnati Wellness Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on December 19, 2025

Dec. 19, 2025

Cannabix Technologies Launches New Marijuana Breath Test Product Videos as U.S. Cannabis Reclassification Underscores the Urgent Need for Innovative Public Safety Solutions

GlobeNewswire

Dec. 19, 2025

EMJX Enhances Gen2 Digital Asset Treasury Operating System On OpenAI’s Large Language Models (LLMs) for Research and Risk Decision Support

GlobeNewswire

Dec. 19, 2025

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

GlobeNewswire

Dec. 19, 2025

Jyong Biotech Responds to Share Price and Volume Movement

GlobeNewswire

Dec. 19, 2025

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

GlobeNewswire

Dec. 19, 2025

NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals

GlobeNewswire

Dec. 19, 2025

Sienna Completes Acquisition in the Greater Toronto Area

GlobeNewswire

Dec. 19, 2025

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

GlobeNewswire

Dec. 19, 2025

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

GlobeNewswire

Dec. 19, 2025

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

GlobeNewswire

Dec. 19, 2025

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

GlobeNewswire

Dec. 19, 2025

Cue Biopharma Announces Pricing of $10 Million Public Offering

GlobeNewswire

Dec. 19, 2025

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

GlobeNewswire

Dec. 19, 2025

Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update

GlobeNewswire

Dec. 19, 2025

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

GlobeNewswire

Dec. 19, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Dec. 19, 2025

OKYO Pharma to Ring the Opening Bell at Nasdaq

GlobeNewswire

Dec. 19, 2025

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

GlobeNewswire

Dec. 19, 2025

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

GlobeNewswire

Dec. 19, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire